Abstract 2042P
Background
Breast cancer is the most diagnosed cancer affecting Australian women. While the incidence rate of breast cancer is lower in indigenous women than non-indigenous women the mortality rate is higher, with indigenous women 1.2 times more likely to die from the disease. The are many factors that contribute to this and if we want outcomes to improve for indigenous women with breast cancer, we must identify where practice and policy can change and improve. These findings may inform approaches for indigenous women in other high-income countries who experience similarly poor breast cancer outcomes.
Methods
This research employed the Context-Mechanism-Outcome (CMO) framework to reveal potential mechanisms and contextual factors that influence breast cancer outcomes for indigenous women. The framework explains generative causation, which helps to highlight the relationship between a context, mechanism, and outcome of a program or policy. The mechanisms and contextual factors were stratified into multiple levels; micro (interpersonal), meso (systemic), and macro (policy) levels. “If-Then-Because” statements were used to represent (broadly) the elements of CMO.
Results
The CMO framework allowed us to interpret evidence regarding indigenous women and breast cancer and provided nine practical ways to improve health outcomes and survival rates: 1. Improved health literacy regarding the importance of screening and early detection, delivered in a culturally safe way 2. Increased cultural safety and access to screening services 3. Presence of indigenous health service providers 4. Ensuring health service provider is local and/or familiar with indigenous culture and community 5. Culturally safe screening, diagnosis, treatment and follow-up settings 6. Local indigenous screening champions in the community 7. Protocols for abnormal results are tailored to local setting and community 8. Culturally safe support available for people who receive diagnoses 9. Policy is re-written in consultation with indigenous people and provides solutions to improve health outcomes.
Conclusions
Using the CMO framework, this study has provided nine practical measures to assist in improving the health outcomes for Australian indigenous women with breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
V. Christie.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06